1. Home
  2. AFRM vs ILMN Comparison

AFRM vs ILMN Comparison

Compare AFRM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Affirm Holdings Inc.

AFRM

Affirm Holdings Inc.

HOLD

Current Price

$79.05

Market Cap

28.3B

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$190.40

Market Cap

26.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AFRM
ILMN
Founded
2012
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.3B
26.7B
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
AFRM
ILMN
Price
$79.05
$190.40
Analyst Decision
Buy
Hold
Analyst Count
25
17
Target Price
$84.52
$124.24
AVG Volume (30 Days)
3.2M
1.9M
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
108.98
170.87
EPS
0.90
2.22
Revenue
$3,224,412,000.00
$4,343,000,000.00
Revenue This Year
$30.78
$6.47
Revenue Next Year
$23.95
$5.58
P/E Ratio
$87.00
$86.75
Revenue Growth
38.80
N/A
52 Week Low
$42.10
$88.00
52 Week High
$100.00
$207.00

Technical Indicators

Market Signals
Indicator
AFRM
ILMN
Relative Strength Index (RSI) 55.88 50.35
Support Level $71.24 $117.64
Resistance Level $79.79 $196.66
Average True Range (ATR) 3.44 7.76
MACD 0.36 -1.66
Stochastic Oscillator 82.44 22.18

Price Performance

Historical Comparison
AFRM
ILMN

About AFRM Affirm Holdings Inc.

Founded in 2012, Affirm is a market leader in the buy now, pay later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also constitute the majority of its revenue. Affirm primarily operates in the United States, which accounted for more than 95% of its revenue in 2025, but it has also expanded to Canada and the United Kingdom.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: